Cancer treatment firm Sirtex Medical has won reimbursement from the Netherlands Healthcare Institute (Zorginstituut Nederland, ZIN) for its selective internal radiation therapy technology (SIRT) for certain applications in patients with colorectal cancer.
ZIN agreed to pay for SIRT procedures in patients with colorectal liver metastases who have failed or are on prior chemotherapy. The institute based its decision on clinical evidence of the efficacy and safety of the company's SIRSpheres Y-90 resin microspheres for this application, the company said.
In addition, Sirtex reported the Netherlands cancer organization, Integraal Kankercentrum Nederland (IKNL), will manage a new patient registry to collect and analyze treatment data on the first 500 patients with colorectal liver metastases who receive SIRT under the new reimbursement program. The treatment will be made available to patients in the Netherlands through 10 specialist centers.
